Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity

Table 4 Urinary toxicity prognostic factors

Characteristics	Bivariate analysis		Multivariate analysis
Characteristics	HR and 95% CI	p-value	HR and 95% CI	p-value
Age^a
≤70	1
>70	1.15 [0.69; 1.91]	0.59	-	-
Stage
T1c + 2a	1
T2b	0.86 [0.40; 1.85]	0.70
T2c-T4	1.27 [0.70; 2.30]	0.43
Diabetes^a
No	1
Yes	1.96 [1.09; 3.54]	0.02	-	-
HBP
No	1
Yes	1.02 [0.61; 1.70]	0.95
Pelvic surgery
No	1
Yes	1.18 [0.59; 2.0]	0.53
Previous TURP^a
No	1
Yes	0.29 [0.09; 0.94]	0.04	-	-
Androgen deprivation
No	1
<6m	1.28 [0.71; 2.30]	0.41
>6m	1.15 [0.60; 2.21]	0.67	-	-
Anticoagulation treatment^a
No	1
Yes	0.71 [0.41; 1.21]	0.20	-	-
RTH total dose
70 Gy	1
74 Gy	0.71 [0.33;1.54]	0.38
80 Gy	0.84 [0.37;1.92]	0.70
RTH total dose^a
70Gy-74Gy	1
80 Gy	1.1 [0.64; 1.92]	0.70	-	-
IPSS baseline^a
0–7	1
≥8	2.43 [1.37; 4.31]	<0.01	2.43 [1.37; 4.31]	<0.01

Abbreviations: HR hazard ratio, 95% CI 95% confidence interval, HBP high blood pressure, TURP transurethral prostate resection, anticoagulation treatment anticoagulation or antiplatelet treatment, RTH radiotherapy, IPSS international prostate score symptom
^aParameters included in backward multivariate analysis

ISSN: 1748-717X